ONCOLYTICS BIOTECH INC
ONCYNASDAQEarnings Oct 30US Equity
$0.44—
Last available close · quote unavailableTrack ONCY
Get earnings, price moves & breaking news on Telegram
24h—
7d▼ 12.4%
14d▼ 19.3%
30d▼ 33.6%
ytd▼ 48.8%
1y▼ 61.9%
🏦Market Cap
—
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- —
- 52-Week Range
- $1.48 – $4.49
- Volume (shares)
- —
- Avg Volume (shares)
- —
- Shares Outstanding
- 131.1M
- Next Earnings
- 2026-10-30
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-0.37
- Dividend Yield
- —
- Dilution (1yr)
- +35.0%
ONCOLYTICS BIOTECH INC
ONCYFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$29M▲ +12.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$20M▲ +0.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
108.0M▲ +35.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$5M▼ −$10M YoY
StockOtter · stockotter.spaceAbout ONCOLYTICS BIOTECH INC
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
8 analysts
Strong Buy1
Buy5
Hold2
Sell0
Strong Sell0
Ratings as of Jun 2026
Latest News & Updates
News unavailable.